Causes of False-Positive ANA Tests
False-positive ANA results occur commonly in healthy individuals (up to 25% depending on demographics and cut-off values), as well as in patients with infections, malignancies, drug exposures, and various non-rheumatic conditions—making clinical context essential for interpretation. 1
Healthy Individuals and Demographics
- Healthy population prevalence: Up to 25% of apparently healthy individuals can test ANA-positive by IIFA, depending on the population studied, serum dilution, and cut-off thresholds used. 1
- Age and sex factors: ANA positivity is more common in older individuals and females, even without autoimmune disease. 2
- Clinical significance: In the general population, many individuals with positive ANA tests do not have autoimmune disease and are unlikely to develop one. 1
- High-titer ANAs: Even at titers ≥1:640, approximately 2% of the general population tests positive without having autoimmune disease. 3
Infectious Diseases
- Acute and chronic infections are well-recognized causes of positive ANA tests, particularly when testing is performed in patients with non-specific symptoms like fever, joint pain, or fatigue. 4
- Common infectious causes include:
- Intracellular infections such as mycobacterial infections, syphilis, and scrub typhus show particular association with ANA positivity. 5
Drug-Induced ANA Positivity
Cardiovascular drugs are notable culprits for inducing ANA, categorized into two groups: 2
Category A (High-frequency induction with SLE-like syndromes):
- Procainamide (induces ANA in most patients with prolonged high-dose therapy) 2
- Hydralazine at high doses 2
- Practolol 2
Category B (20-30% incidence, rarely causing SLE):
Other beta-blockers (atenolol, metoprolol, oxprenolol) show mildly increased ANA incidence without associated SLE. 2
Non-Rheumatic Diseases
- Malignancies: Various cancers can produce positive ANA results. 6
- Liver disorders: High ANA titers (≥1:640) in non-autoimmune individuals show strong association with liver disorders, liver complications, and risk factors for liver disease. 3
- Environmental exposures: Non-specific environmental factors can trigger ANA positivity. 6
Technical and Methodological Factors
- Assay variability: The false-positive ratio differs between IIFA and alternative methods (ELISA, chemiluminescence, etc.), with each platform having distinct test characteristics. 1
- Cut-off selection: The screening dilution and cut-off threshold significantly impact false-positive rates; a 1:160 dilution on HEp-2 substrates is generally suitable for adult populations, representing the 95th percentile of healthy controls. 1
- Laboratory quality: IIFA is only as good as the laboratory performing it, requiring substantial technical expertise and trained personnel. 1
Interference from Other Autoantibodies
- ANA interference with ANCA testing: Positive ANA can cause false-positive p-ANCA patterns on ethanol-fixed substrates, particularly at higher ANA titers (77.3% of ANA-positive samples showed p-ANCA patterns). 7
- Cross-reactivity: ANA can interfere with C-ANCA detection by indirect immunofluorescence, potentially leading to misdiagnosis of vasculitis. 8
- Coexisting autoantibodies: Up to 32-48% of patients with certain myositis-specific antibodies also have positive ANA titers ≥1:400, complicating interpretation. 9
Critical Clinical Pitfalls
- Inappropriate screening: ANA testing should not be used to evaluate patients with vague complaints or non-specific symptoms, as this dramatically increases false-positive rates. 10, 6
- Pre-test probability: The performance of any ANA assay is highly dependent on pre-test probability; interpretation must be governed by clinical circumstances and presence of rheumatic disease signs/symptoms. 1
- Method specification: Clinicians are often unaware of which method was used for ANA detection and may erroneously apply IIFA test characteristics to other methods. 1